HUP0102514A2 - Sejtburjánzás gátló hatású pirido-pirimidin és pirimido-pirimidin-származékok és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Sejtburjánzás gátló hatású pirido-pirimidin és pirimido-pirimidin-származékok és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0102514A2
HUP0102514A2 HU0102514A HUP0102514A HUP0102514A2 HU P0102514 A2 HUP0102514 A2 HU P0102514A2 HU 0102514 A HU0102514 A HU 0102514A HU P0102514 A HUP0102514 A HU P0102514A HU P0102514 A2 HUP0102514 A2 HU P0102514A2
Authority
HU
Hungary
Prior art keywords
group
alkyl
pyrimidin
atom
double bond
Prior art date
Application number
HU0102514A
Other languages
English (en)
Inventor
Ellen Myra Dobrusin
James Marino Hamby
James Bernard Kramer
Mel Conrad Schroeder
Howard Daniel Hollis Showalter
Peter Toogood
Susanne A. Trumpp-Kallmeyer
Original Assignee
Warner-Lambert Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26775058&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0102514(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Co. filed Critical Warner-Lambert Co.
Publication of HUP0102514A2 publication Critical patent/HUP0102514A2/hu
Publication of HUP0102514A3 publication Critical patent/HUP0102514A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A találmány tárgya (I) általános képletű vegyületek és gyógyászatilagalkalmazható sóik, ahol: a szaggatott vonal egy adott esetben jelenlévő kettős kötést jelent; Z jelentése N atom vagy CH csoport; Gjelentése N atom vagy CH csoport; W jelentése NH csoport, S atom, SO,vagy SO2 csoport; X jelentése O, S atom, vagy NR10 csoport; R1, R2, ésR10 jelentése egymástól függetlenül H atom, (CH2)nAr, COR4,(CH2)nheteroaril, (CH2)nheterociklil, C1-C10-alkil, C3-C-cikloalkil,C2-C10- alkenil- és C2-C10-alkinilcsoport, ahol n = 0, 1, 2, vagy 3,és a (CH2)nAr, (CH2)nheteroaril, alkil, cikloalkil, alkenil- ésalkinilcsoportok adott esetben legfeljebb 5 csoporttalszubsztituáltak, ahol kettős kötés van jelen, az R3 csoport hiányzik;másrészt R3 jelentése R2 jelentéseivel azonos, ahol R2 jelentése afentiekben megadott, valamint OH, NR4R5, COOR4, OR4, CONR4R5,SO2NR4R5, SO3R4, PO3R4 csoport, csoport, ahol T és Q jelentése afentiekben megadott; R6 jelentése alkilcsoport; R8 és R9 jelentéseegymástól függetlenül H atom, C1-C3-alkil, NR4R5, N(O)R4R5, NR4R5R6Y,hidroxil, alkoxi, tiol, tio-alkilcsoport, halogénatom, COR4, CO2R4,CONR4R5, SO2NR4R5, SO3R4, PO3R4, CHO, CN, vagy NO2 csoport; ha akettős kötés hiányzik, R9 jelentése még karbonil, tio-karbonil, iminés szubsztituált imincsoport, oxim és oxim-éter, és Y jelentése egyhalogén ellenion. A találmány szerinti vegyületek ciklin-függő kinázés tirozin kináz enzim gátló hatásúak és így proliferatív betegségekkezelésében alkalmazhatók. A találmány tárgyát képezik a fentivegyületeket tartalmazó gyógyszerkészítmények. Ó
HU0102514A 1998-05-26 1999-05-10 Pyrido-pyrimidin and pyrimido-pyrimidin derivatives as inhibitors of cellular proliferation and pharmaceutical compositions thereof HUP0102514A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8670898P 1998-05-26 1998-05-26
US12615899P 1999-03-25 1999-03-25
PCT/US1999/010187 WO1999061444A2 (en) 1998-05-26 1999-05-10 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

Publications (2)

Publication Number Publication Date
HUP0102514A2 true HUP0102514A2 (hu) 2001-11-28
HUP0102514A3 HUP0102514A3 (en) 2002-03-28

Family

ID=26775058

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102514A HUP0102514A3 (en) 1998-05-26 1999-05-10 Pyrido-pyrimidin and pyrimido-pyrimidin derivatives as inhibitors of cellular proliferation and pharmaceutical compositions thereof

Country Status (29)

Country Link
US (1) US7501425B1 (hu)
EP (1) EP1080092B1 (hu)
JP (1) JP2002516327A (hu)
KR (1) KR20010043829A (hu)
CN (1) CN1138778C (hu)
AP (1) AP2000001964A0 (hu)
AT (1) ATE402177T1 (hu)
AU (1) AU763839B2 (hu)
BG (1) BG104960A (hu)
BR (1) BR9911590A (hu)
CA (1) CA2329703C (hu)
DE (1) DE69939168D1 (hu)
EA (1) EA003640B1 (hu)
EE (1) EE200000706A (hu)
ES (1) ES2310039T3 (hu)
GE (1) GEP20033093B (hu)
HK (1) HK1039483A1 (hu)
HR (1) HRP20000799A2 (hu)
HU (1) HUP0102514A3 (hu)
ID (1) ID27589A (hu)
IL (1) IL139599A0 (hu)
IS (1) IS5687A (hu)
NO (1) NO20005928D0 (hu)
NZ (1) NZ508268A (hu)
PL (1) PL344248A1 (hu)
SK (1) SK17532000A3 (hu)
TR (1) TR200003429T2 (hu)
WO (1) WO1999061444A2 (hu)
YU (1) YU73300A (hu)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310039T3 (es) 1998-05-26 2008-12-16 Warner-Lambert Company Llc Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.
PL347432A1 (en) * 1998-10-23 2002-04-08 Hoffmann La Roche Bicyclic nitrogen heterocycles
DE60032623T2 (de) * 1999-10-21 2007-10-11 F. Hoffmann-La Roche Ag Alkylamino-substituierte bicyclische heterocyclen als p38 protein-kinase-inhibitoren
CN1171889C (zh) * 1999-10-21 2004-10-20 霍夫曼-拉罗奇有限公司 作为p38蛋白激酶的抑制剂的杂烷基氨基－取代的双环氮杂环类化合物
AP2002002603A0 (en) * 2000-01-24 2002-09-30 Warner Lambert Co 3-aminoquinazolin-2,4-dione antibacterial agents.
MXPA02007221A (es) * 2000-01-25 2002-11-29 Warner Lambert Co Inhibidores de pirido [2,3-d)pirimidin-2,7-diamina cinasa.
US7053070B2 (en) 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
AR030053A1 (es) * 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
DZ3308A1 (fr) * 2000-03-06 2001-09-27 Warner Lambert Co Inhibiteurs de tyrosine kinase a base de 5-alkylpyrido [2,3-d] pyrimidines
KR100571339B1 (ko) * 2000-08-31 2006-04-17 에프. 호프만-라 로슈 아게 세포증식 억제제로서의 7-옥소 피리도피리미딘
US6506749B2 (en) 2000-08-31 2003-01-14 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (I)
JP4524072B2 (ja) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
GB0029015D0 (en) 2000-11-28 2001-01-10 Univ London Medical device
WO2002060382A2 (en) 2001-01-19 2002-08-08 Smithkline Beecham Corporation Novel compounds and uses thereof
CA2434834C (en) 2001-02-12 2010-09-14 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
US7105667B2 (en) 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
BR0210099A (pt) 2001-05-30 2004-04-13 Warner Lambert Co Agentes antibacterianos
IL162721A0 (en) * 2002-01-22 2005-11-20 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyridoÄ2,3-dÜpyrimidin-7-ones
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
US7629350B2 (en) 2002-04-19 2009-12-08 Smithkline Beecham Corporation Compounds
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
EP1539755B1 (en) 2002-08-06 2007-09-26 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
TW200413381A (en) * 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US7129351B2 (en) * 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
BRPI0406809A (pt) * 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
RU2350617C2 (ru) * 2003-04-10 2009-03-27 Ф.Хоффманн-Ля Рош Аг Пиримидиновые соединения, обладающие свойствами селективного ингибирования активности кдр и фрфр
DE10325133A1 (de) * 2003-06-04 2004-12-23 Bayer Cropscience Ag Triazolopyrimidine
US7371750B2 (en) 2003-07-29 2008-05-13 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0416030A (pt) 2003-11-13 2007-01-02 Hoffmann La Roche pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
DE602005013248D1 (de) 2004-08-31 2009-04-23 Hoffmann La Roche Amidderivate von 3-phenyldihydropyrimidoä4,5-düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
BRPI0514750A (pt) 2004-08-31 2008-06-24 Hoffmann La Roche derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
CA2590294A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
AR053450A1 (es) 2005-03-25 2007-05-09 Glaxo Group Ltd Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38
EP1868612A4 (en) 2005-03-25 2010-03-24 Glaxo Group Ltd NOVEL CONNECTIONS
EA200702073A1 (ru) 2005-03-25 2008-12-30 Глэксо Груп Лимитед Способ получения пиридо[2,3-d]пиримидин-7-оновых и 3,4-дигидропиримидо[4,5-d]пиримидин-2(1н)-оновых производных
CA2636981A1 (en) 2006-01-31 2007-08-09 F. Hoffmann-La Roche Ag 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
CN101784551A (zh) * 2007-06-15 2010-07-21 万有制药株式会社 二环苯胺衍生物
JP5524084B2 (ja) 2008-02-01 2014-06-18 武田薬品工業株式会社 Ｈｓｐ９０阻害剤としてのオキシム誘導体
US8507505B2 (en) 2008-12-12 2013-08-13 Msd K.K. Dihydropyrazolopyrimidinone derivative
CA2745959A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
JP5908728B2 (ja) * 2009-01-06 2016-04-26 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法
CA2750716A1 (en) * 2009-02-25 2010-09-02 Msd K.K. Pyrimidopyrimidoindazole derivative
SA111320200B1 (ar) * 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
CA2807498C (en) * 2010-08-05 2017-02-07 Temple University-Of The Commonwealth System Of Higher Education 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
SG10201702654VA (en) 2011-04-22 2017-06-29 Signal Pharm Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
EP3309148A1 (en) 2011-10-14 2018-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2572908T3 (es) 2011-10-14 2016-06-03 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
JP6033318B2 (ja) 2011-10-14 2016-11-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物
LT3176170T (lt) 2012-06-13 2019-04-25 Incyte Holdings Corporation Pakeisti tricikliniai junginiai, kaip fgfr inhibitoriai
DK2872491T3 (da) * 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906551B1 (en) 2012-10-12 2018-02-28 Bristol-Myers Squibb Company Crystalline forms of a factor xia inhibitor
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
US9663524B2 (en) 2013-03-15 2017-05-30 Celgene Car Llc Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors
UA120248C2 (uk) 2013-03-15 2019-11-11 Селджен Кар Ллс Гетероарильні сполуки та їх застосування
EP2978751B1 (en) 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
DK2986610T5 (en) * 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
EP3019491A4 (en) 2013-07-09 2016-12-21 Dana Farber Cancer Inst Inc KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
SI3057943T1 (en) 2013-10-18 2018-08-31 Eisai R&D Management Co., Ltd. Pyrimidine FGFR4 Inhibitors
EP3060560A1 (en) 2013-10-25 2016-08-31 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
SG11201604821YA (en) 2013-12-20 2016-07-28 Signal Pharm Llc Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
LT3099687T (lt) 2014-01-31 2018-09-10 Bristol-Myers Squibb Company Makrociklai su heterociklinėmis p2' grupėmis kaip faktoriaus xia inhibitoriai
NO2760821T3 (hu) 2014-01-31 2018-03-10
CN103880861B (zh) * 2014-02-21 2016-02-03 温州医科大学 一种作用于FGF受体的4,6-二甲基-噁唑并[5,4-d]嘧啶-5,7（4H,6H）-二酮衍生物
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN107438607B (zh) 2015-02-20 2021-02-05 因赛特公司 作为fgfr抑制剂的双环杂环
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CA2982562C (en) 2015-04-14 2023-06-13 Eisai R&D Management Co., Ltd. Crystalline fgfr4 inhibitor compound and uses thereof
US11357769B2 (en) 2016-05-10 2022-06-14 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
CN107459519A (zh) * 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
EP4047001A3 (en) * 2016-07-05 2022-11-30 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018160774A1 (en) 2017-02-28 2018-09-07 The General Hospital Corporation Uses of pyrimidopyrimidinones as sik inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019213506A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
PE20210920A1 (es) 2018-05-04 2021-05-19 Incyte Corp Formas solidas de un inhibidor de fgfr y procesos para prepararlas
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220100879A (ko) 2019-10-14 2022-07-18 인사이트 코포레이션 Fgfr 저해제로서의 이환식 헤테로사이클
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
CA3188639A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202302589A (zh) 2021-02-25 2023-01-16 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949466A (en) 1958-03-04 1960-08-16 Parke Davis & Co Pyrimidine compounds and means of producing the same
ES338687A1 (es) 1966-04-06 1968-04-01 Monsanto Co Procedimiento para obtener composiciones de fluidos funcio-nales.
US3912723A (en) 1971-03-29 1975-10-14 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
IE49992B1 (en) 1979-06-14 1986-01-22 Wellcome Found Alkoxybenzylpyridopyrimidines,methods for their preparation and pharmaceutical formulations thereof
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
JPS60226882A (ja) 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
AU598093B2 (en) 1987-02-07 1990-06-14 Wellcome Foundation Limited, The Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
EP0584222B1 (en) * 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
CA2200468A1 (en) 1994-10-27 1996-05-09 Wayne J. Thompson Muscarine antagonists
TJ342B (en) * 1994-11-14 2002-10-06 Warner Lambert Co Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
CA2249446C (en) * 1996-04-12 2008-06-17 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
JP2001509805A (ja) 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー 細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6150359A (en) 1997-08-20 2000-11-21 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
JP4038624B2 (ja) 1997-11-29 2008-01-30 日本農薬株式会社 縮合複素環誘導体及びその中間体並びに有害生物防除剤
ES2310039T3 (es) 1998-05-26 2008-12-16 Warner-Lambert Company Llc Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.
PL347432A1 (en) * 1998-10-23 2002-04-08 Hoffmann La Roche Bicyclic nitrogen heterocycles
CN1171889C (zh) 1999-10-21 2004-10-20 霍夫曼-拉罗奇有限公司 作为p38蛋白激酶的抑制剂的杂烷基氨基－取代的双环氮杂环类化合物
DE60032623T2 (de) 1999-10-21 2007-10-11 F. Hoffmann-La Roche Ag Alkylamino-substituierte bicyclische heterocyclen als p38 protein-kinase-inhibitoren
AR030053A1 (es) 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas

Also Published As

Publication number Publication date
EP1080092B1 (en) 2008-07-23
AP2000001964A0 (en) 2000-12-31
CN1138778C (zh) 2004-02-18
IL139599A0 (en) 2002-02-10
EP1080092A2 (en) 2001-03-07
ES2310039T3 (es) 2008-12-16
US7501425B1 (en) 2009-03-10
YU73300A (sh) 2003-08-29
EA003640B1 (ru) 2003-08-28
NO20005928L (no) 2000-11-23
AU763839B2 (en) 2003-07-31
ATE402177T1 (de) 2008-08-15
GEP20033093B (en) 2003-10-27
HUP0102514A3 (en) 2002-03-28
AU4073499A (en) 1999-12-13
TR200003429T2 (tr) 2001-07-23
NZ508268A (en) 2004-02-27
CN1302301A (zh) 2001-07-04
HK1039483A1 (en) 2002-04-26
BR9911590A (pt) 2001-02-13
CA2329703A1 (en) 1999-12-02
DE69939168D1 (de) 2008-09-04
IS5687A (is) 2000-10-27
WO1999061444A2 (en) 1999-12-02
JP2002516327A (ja) 2002-06-04
KR20010043829A (ko) 2001-05-25
CA2329703C (en) 2005-12-20
SK17532000A3 (sk) 2002-08-06
PL344248A1 (en) 2001-10-22
NO20005928D0 (no) 2000-11-23
BG104960A (en) 2001-10-31
EE200000706A (et) 2002-06-17
HRP20000799A2 (en) 2001-06-30
WO1999061444A3 (en) 2000-02-03
ID27589A (id) 2001-04-12
EA200001171A1 (ru) 2001-06-25

Similar Documents

Publication Publication Date Title
HUP0102514A2 (hu) Sejtburjánzás gátló hatású pirido-pirimidin és pirimido-pirimidin-származékok és ezeket tartalmazó gyógyszerkészítmények
IL129068A0 (en) Sulfinic acid derivatives and their preparation and use
DE69809754D1 (en) Substituierte 6-phenylphenanthridine
GEP20012413B (en) Novel Substituted Cyclic Amino Acids as Pharmaceutical Agents
ES2180633T3 (es) Uso de derivados de pteridina como inhibidores de la no-sintasa.
HUP0100757A1 (hu) Foszfilopáz enzim inhibitor hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyászati készítmények
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
HUP0401646A2 (hu) Tumorellenes hatású kinazolinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0100156A2 (hu) Foszfolipáz-A2 inhibitor hatású indolszármazékok és alkalmazásuk gyógyászati készítmények előállítására
NO964058D0 (no) Pyrimidinylderivater som interleukininhibitorer
HUP0103460A2 (hu) Vírusellenes hatású indolszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények
IL94433A0 (en) Aminophenol derivatives,their preparation and pharmaceutical compositions containing them
HUP0202788A2 (hu) Terápiásan hasznosítható tulajdonságokkal rendelkező indolil-3-glioxilsav-származékok és ezeket tartalmazó gyógyszerkészítmények
HUP0000664A2 (hu) Azinil-oxi- és fenoxi-diaril-karbonsavszármazékok, eljárás előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
HUP0301478A2 (hu) Antibakteriális aktivitású pleuromutilinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BR0209452A (pt) Composto de cefem, processo para sua preparação, composição farmacêutica e uso do composto
DE69525740T2 (de) Spezielle halofantrinhaltige Zusammensetzungen
HUP0402076A2 (hu) Szubsztituált indolok, eljárás az előállításukra és fájdalomcsillapítókénti alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DE69834047D1 (de) Verwendung einer Zubereitung und ein kosmetisches Verfahren zur Verminderung und Vorbeugung von beissender der Haut
IL102361A0 (en) Benzomorphan derivatives,their preparation and pharmaceutical compositions containing them
HUP9702227A2 (hu) Új benzopiránvegyületek, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények
NZ310385A (en) Novel derivatives of swainsonine, processes for their preparation and their use as therapeutic agents
ES2104416T3 (es) Glicosilamidas de 2-aminoacilamino-2-desoxi-azucares.
HUP9801451A2 (hu) Tetrahidroimidazo[2,1-a]izokinolin-származékok és ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees